about
Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.Elevated hypercoagulability markers in hemoglobin SC disease.Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.PTK2 and PTPN11 expression in myelodysplastic syndromes.De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.Stathmin 1 in normal and malignant hematopoiesis.Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.Differential profile of PIP4K2A expression in hematological malignancies.ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells.ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells.Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells.Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines.ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells.Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.Stathmin 1 expression in plasma cell neoplasms.BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms.Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cellsSomatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms.Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations.Gene expression analysis of the Brazilian type of hereditary persistence of fetal hemoglobin: identification of genes that could be related to γ-globin activation.IRS1/β-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells.The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation.FMNL1 promotes proliferation and migration of leukemia cells.Reversine triggers mitotic catastrophe and apoptosis in K562 cells.Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.Serine peptidase inhibitor Kunitz type 2 (SPINT2) in cancer development and progression.Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome.Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia.Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients.Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome.Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.PIPKIIα is widely expressed in hematopoietic-derived cells and may play a role in the expression of alpha- and gamma-globins in K562 cells.YAP1 expression in myelodysplastic syndromes and acute leukemias.Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells.Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis.IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes.
P50
Q33588161-CCA13AC4-B4CD-44AC-99B1-582B40B7C6CFQ35028968-84BC5907-BBDA-4C2E-9CF5-3C1447A901A8Q35236050-7F88B14E-627E-463F-939B-B879E9318E87Q36691624-1167CE2B-CC4F-42B3-BAF2-BBC284EF2963Q36916389-13749FB0-CB6B-41D2-8459-CEFAB2A53C5BQ37234608-914288B4-F2A8-4391-9A49-E149B0D8A884Q37584726-169008D2-7466-48B7-8941-0A07F2672994Q38199283-E2F11802-2CDE-4D59-B67E-DA3102804A3BQ38795770-BDA5707E-AF4F-46A9-8096-1F34B6687290Q38847696-0C906671-6143-4222-8CFC-A47745CCB506Q39004834-5012A440-5C5E-441D-A95C-A881717325B0Q39234913-03A94DEB-16CF-4625-9218-CFD81D7E9B0BQ39543191-6A5C7EBD-090B-43C3-80D2-AE0724F39121Q41186755-7E4B8BEE-FA97-40D1-8DAA-667AD832225BQ41671217-0EA14647-0A18-436C-8B57-9C43BC203D25Q41754225-51BE3E34-FE93-4EC9-83E9-1CCF46D4CCB6Q42342978-A7144E43-2543-4D1A-9F48-CA9B930D5107Q42362055-41EE4C4A-2497-48EC-B55A-57405F178700Q42364661-E69BF6B1-BE27-497B-9726-A0664AF3661DQ42371082-535A1088-BEF8-4C80-87D5-6B6B7F5005FBQ42585822-3C9C1502-0C15-4646-A2FB-6D039664BE56Q47107319-E33D6E2D-76C8-4A8E-B830-F2BD14BD34A5Q47764292-D5DE2328-021B-4C84-A24D-68B5A2F30061Q48143888-25286865-DD9D-4C32-AD4D-479B3EE1A7AEQ50144617-BB1336EF-CD1A-4BC8-8789-D68A03100403Q50337087-0E8A63CC-9ADA-46D1-85D6-BC8A3AB25C53Q51623731-36948B5D-4290-43F8-AF15-464A27A49A21Q51748677-FAAD8F98-85A7-42FC-ACB4-426F58AA50F7Q52676902-7D8A31AF-E477-438A-803C-CEA84A70FCF0Q52837423-D70719F2-25E8-49DF-8DC9-1889C7399E39Q52926775-8C53B6EF-6F3A-4D84-BFCE-9B4CCB0D77C9Q54299957-754EFF42-7945-4186-AA3E-E5C90F61D449Q54301379-F61AA1CA-4279-45A2-B48C-F0EC37B4C208Q54306741-CAEE055A-4A2B-4D82-92CC-038A3EF153EFQ54328476-F1EFD97F-DABD-4CFC-804A-5FE8AB6FEAF8Q54355757-AE7DDF73-976C-4FAE-B080-815B9F4BC420Q54372329-09FB1BDC-56A3-47A4-9C9F-B0852F5CD9B5Q54416532-F2AE00CC-D56A-4499-9DFB-5E9A33D69176Q55026474-61A52E25-1349-496B-9086-1993E327DB1BQ55361133-489331FA-9C33-467E-8633-AC13BE227027
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
João Agostinho Machado-Neto
@ast
João Agostinho Machado-Neto
@en
João Agostinho Machado-Neto
@es
João Agostinho Machado-Neto
@nl
João Agostinho Machado-Neto
@sl
type
label
João Agostinho Machado-Neto
@ast
João Agostinho Machado-Neto
@en
João Agostinho Machado-Neto
@es
João Agostinho Machado-Neto
@nl
João Agostinho Machado-Neto
@sl
prefLabel
João Agostinho Machado-Neto
@ast
João Agostinho Machado-Neto
@en
João Agostinho Machado-Neto
@es
João Agostinho Machado-Neto
@nl
João Agostinho Machado-Neto
@sl
P1053
L-8975-2016
P106
P1153
40761630500
P21
P31
P3829
P496
0000-0002-2937-8109